Clinical efficacies of antihypertensive drugs

Scandinavian Cardiovascular Journal

Volumn 37, Issue 2, 2003, Pages 72-79

  Aursnes, Ivar ^a   Tvete, Ingunn Fride ^a,b   Gåsemyr, Jørund ^a   Natvig, Bent ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b NORWEGIAN COMPUTING CENTER   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; CHLOROTHIAZIDE; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; HYDROCHLOROTHIAZIDE; ISRADIPINE; LISINOPRIL; METHYCLOTHIAZIDE; NICARDIPINE; NIFEDIPINE; NISOLDIPINE; NITRENDIPINE; PLACEBO; QUINAPRIL; RAMIPRIL; TRICHLORMETHIAZIDE; VERAPAMIL;

ARTICLE; BAYES THEOREM; CORONARY ARTERY DISEASE; DATA ANALYSIS; DRUG EFFICACY; HEART FAILURE; HUMAN; HYPERTENSION; META ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROBABILITY; PUBLICATION; RISK ASSESSMENT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STROKE;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; DIURETICS; HUMANS; HYPERTENSION; TREATMENT OUTCOME;

EID: 0038820374     PISSN: 14017431     EISSN: None     Source Type: Journal    
DOI: 10.1080/14017430310001186     Document Type: Article

References (39)

1. The Swedish Council on Technology Assessment in Health Care. Måttligt förhöjt blodtryck. Stockholm: SBU-rapport, 1994.
2. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Lancet 2000;356:1955-1964.
3. Aursnes I, Storvik G, Gåsemyr J, Natvig B. A Bayesian analysis of bisphosphonate effects and cost-effectiveness in post-menopausal osteporosis. Pharmacoepid Drug Safety 2000; 9: 501-509.
4. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153.
5. MacMahon S, Sharpe N, Gamble G, et al. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. J Am Coll Cardiol 2000; 36: 438-443.
6. Cashin-Hemphill L, Holmvang G, Chan RC, Pitt B, Dinsmore RE, Lees RS. Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: No answer yet. Am J Cardiol 1999; 83: 43-47.
7. Teo KK, Burton JR, Buller CE, et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/enalapril Coronary Atherosclerosis Trial (SCAT). Circulation 2000; 102: 1748-1754.
8. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-1756.
9. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-720.
10. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616.
11. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-372.
12. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension 1999; 34: 1129-1133.
13. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359-365.
14. Agabiti-Rosei E, Dal Palo C, Leonetti G, Magnani B, Pessina A, Zanchetti A. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. J Hypertens 1997; 15: 1337-1344.
15. Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102: 1503-1510.
16. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-764.
17. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-652.
18. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg. JAMA 1970; 213: 1143-1152.
19. Hypertension-Stroke Cooperative Study Group. Effect of antihypertensive treatment on stroke recurrence. JAMA 1974; 229: 409-418.
20. US Public Health Service Hospitals Cooperative Study Group. Treatment of mild hypertension: Results of a ten-year intervention trial. Circ Res 1977; 40 Suppl 1: 98-105.
21. Veteran Administration-National Heart Lung and Blood Institute Study Group for Evaluating Treatment in Mild Hypertension. Evaluation of drug treatment in mild hypertension. Ann NY Acad Sci 1978; 304: 267-288.
22. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program: I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 1979; 242: 2562-2571.
23. The Management Committee of the Australian Therapeutic Trial in Mild Hypertension. The Australian therapeutic trial in mild hypertension. Lancet 1980; 2: 1261-1267.
24. Helgeland A. Treatment of mild hypertension: A five year controlled drug trial. The Oslo study. Am J Med 1980; 69: 725-732.
25. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: Principal results. BMJ 1985; 291: 97-104.
26. Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985; 1: 1349-1354.
27. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ 1986; 293: 1145-1151.
28. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-3264.
29. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281-1285.
30. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: Principal results. BMJ 1992;304: 405-412.
31. Neaton JD, Grimm RH, Prineas RJ, et al. Treatment of Mild Hypertension Study. Final results. JAMA 1993; 270: 713-724.
32. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-838.
33. Wolff FW, Lindeman RD. Effects of treatment in hypertension: Results of a controlled study. J Chronic Dis 1966; 19: 227-240.
34. Barraclough M, Bainton D, Cochrane AL, et al. Control of moderately raised blood pressure: Report of a co-operative randomised controlled trial. BMJ 1973; iii: 434-436.
35. Carter AB. Hypotensive therapy in stroke survivors. Lancet 1970; i: 485-489.
36. Pahor M, Psaty BM, Alderman MH, et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: A meta-analysis of randomised controlled trials. Lancet 2000; 356: 1949-1954.
37. Staessen JA, Wang J. Blood-pressure lowering for the secondary prevention of stroke. Lancet 2001; 358: 1026-1027.
38. Landmark K, Aursnes I. Infarct size as assessed by peak enzyme levels is reduced in patients who are using angiotensin-converting enzyme inhibitors at the onset of infarction. Clin Drug Invest 2000; 20: 415-423.
39. Grimm RH, Margolis KL, Papademetriou et al. Baseline characteristics of participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2001; 37: 19-27.